58 related articles for article (PubMed ID: 16890193)
21. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
Niu J; Xu Z; Li XN; Han Z
Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
[TBL] [Abstract][Full Text] [Related]
22. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice.
Zhang L; Alizadeh D; Van Handel M; Kortylewski M; Yu H; Badie B
Glia; 2009 Oct; 57(13):1458-67. PubMed ID: 19306372
[TBL] [Abstract][Full Text] [Related]
23. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines.
Gu L; Chiang KY; Zhu N; Findley HW; Zhou M
Exp Hematol; 2007 Jun; 35(6):957-66. PubMed ID: 17533050
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using Bcl-2 siRNA.
Hao JH; Gu QL; Liu BY; Li JF; Chen XH; Ji YB; Zhu ZG; Lin YZ
Chin Med J (Engl); 2007 Dec; 120(23):2105-11. PubMed ID: 18167184
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells.
Lin CP; Liu JD; Chow JM; Liu CR; Liu HE
Anticancer Drugs; 2007 Feb; 18(2):161-70. PubMed ID: 17159602
[TBL] [Abstract][Full Text] [Related]
27. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.
Kinney EL; Tanida S; Rodrigue AA; Johnson JK; Tompkins VS; Sakamuro D
J Cell Physiol; 2008 Sep; 216(3):621-31. PubMed ID: 18348166
[TBL] [Abstract][Full Text] [Related]
28. Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines.
Fukumoto A; Tomoda K; Yoneda-Kato N; Nakajima Y; Kato JY
FEBS Lett; 2006 Oct; 580(25):5836-44. PubMed ID: 17027978
[TBL] [Abstract][Full Text] [Related]
29. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human carcinoma and neuroblastoma cell proliferation by anti-c-myc siRNA.
Kabilova TO; Chernolovskaya EL; Vladimirova AV; Vlassov VV
Oligonucleotides; 2006; 16(1):15-25. PubMed ID: 16584292
[TBL] [Abstract][Full Text] [Related]
31. Attacking c-Myc: targeted and combined therapies for cancer.
Huang H; Weng H; Zhou H; Qu L
Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
[TBL] [Abstract][Full Text] [Related]
32. A high-throughput siRNA screening platform to identify MYC-synthetic lethal genes as candidate therapeutic targets.
Grandori C
Methods Mol Biol; 2013; 1012():187-200. PubMed ID: 24006065
[TBL] [Abstract][Full Text] [Related]
33. Nano-Assembly of Pamitoyl-Bioconjugated Coenzyme-A for Combinatorial Chemo-Biologics in Transcriptional Therapy.
Misra SK; Kampert TL; Pan D
Bioconjug Chem; 2018 Apr; 29(4):1419-1427. PubMed ID: 29466855
[TBL] [Abstract][Full Text] [Related]
34. Models of melanoma metastasis: using a transient siRNA-based protein inhibition strategy in mice to validate the functional relevance of pharmacological agents.
Sharma A; Robertson GP
Curr Protoc Pharmacol; 2007 Sep; Chapter 14():Unit 14.6. PubMed ID: 21948165
[TBL] [Abstract][Full Text] [Related]
35. A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy.
Pan D; Kim B; Hu G; Gupta DS; Senpan A; Yang X; Schmieder A; Swain C; Wickline SA; Tomasson MH; Lanza GM
Nanomedicine (Lond); 2015 Jan; 10(2):241-51. PubMed ID: 25600969
[TBL] [Abstract][Full Text] [Related]
36. Anti-
Habib S; Ariatti M; Singh M
Biomedicines; 2020 Dec; 8(12):. PubMed ID: 33333729
[TBL] [Abstract][Full Text] [Related]
37. A magnetic bead-integrated chip for the large scale manufacture of normalized esiRNAs.
Wang Z; Huang H; Zhang H; Sun C; Hao Y; Yang J; Fan Y; Xi JJ
PLoS One; 2012; 7(6):e39419. PubMed ID: 22761791
[TBL] [Abstract][Full Text] [Related]
38. MYC inhibition, courtesy of E. coli.
O'Leary K
Nat Rev Drug Discov; 2021 Apr; 20(4):264. PubMed ID: 33664419
[No Abstract] [Full Text] [Related]
39. miR-337 can be a key negative regulator in melanoma.
Xiao W; Yao E; Zheng W; Tian F; Tian L
Cancer Biol Ther; 2017 Jun; 18(6):392-399. PubMed ID: 28498028
[TBL] [Abstract][Full Text] [Related]
40. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.
Xiong A; Yang Z; Shen Y; Zhou J; Shen Q
Cancers (Basel); 2014 Apr; 6(2):926-57. PubMed ID: 24743778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
